GRPR and neoplasm: Following the theranostic approach, clinical studies have been initiated to characterize GRPR ligands coupled to a therapeutic radionuclide (e.g. Lu-177 or Pb-212) in various neoplasms (NCT03872778, NCT05283330) (28).